Wyndham Hotels & Resorts, Inc. (NYSE: WH) — The Compounder the Market Mistook for a Cyclical, Marked Down on a One-Time Mess

Report date: 2026-06-13 · Analyst: Claude · Price at writing: ~$79.39 (AZI mark 2026-06-12; ~28% below the early-2024 ~$110 high)

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information, not investment advice. Everything below it (the main analysis) takes no position and carries no price target, by design.

Verdict: BUY / accumulate — the better-executing of the two economy/midscale franchisors, a genuinely multi-vector compounder de-rated to a fair price by a cyclical RevPAR trough and a one-time GAAP-optics mess. More constructive than my HOLD on its sibling Choice, with a real margin of safety in the quality of the growth, not the cheapness of the multiple. Wyndham is the world’s largest hotel franchisor by property count, and unlike Choice — whose legacy economy core is net-deflagging — Wyndham grew net units +4% straight through a RevPAR downcycle, off a record development pipeline now in its 23rd consecutive quarter of growth, with a structural FeePAR up-mix and a fast-growing, RevPAR-insensitive ancillary (credit-card) fee stream. The market is not seeing this because the headline numbers are ugly: GAAP diluted EPS fell to $2.50 in 2025 (a 31x trailing P/E that screens “expensive cyclical”), and the stock has de-rated ~28% to ~$79. But the $2.50 is a mirage — it absorbs ~$160M of one-time, non-cash charges from the insolvency of a single European franchisee (Revo / Vienna House). Strip it and Adjusted EBITDA actually grew to $718M (+4%) and adjusted EPS to $4.58 (+6%) — on a negative RevPAR year. That is the whole thesis: a franchise machine compounding mid-to-high-single-digit per-share earnings on flat-to-down RevPAR, priced as if the RevPAR weakness is the entire story.

The framing is “de-rated quality-ish cyclical / compounder-at-a-fair-price,” not deep value and not a momentum chase. At ~11.3x forward EV/adjusted EBITDA, ~17x forward adjusted EPS ($4.62–4.80 guided), an ~8% free-cash-flow yield, and the 52nd percentile of its own post-spin price/sales range (ignore the GAAP-distorted P/E and the buyback-thinned P/B), you are paying a fair multiple for the cash flows and getting the RevPAR-recovery option largely for free — and the Q1-2026 tape already inflected (US RevPAR Jan −4% → Feb/Mar/Apr +1%). The factor read confirms an abandoned-value name with a nascent turn (negative momentum, value tilt, but a +23.5% three-month reversal). My fair-value zone is roughly $95–$115 (~12–13x EV/EBITDA on a growing ~$770–810M FY27 adjusted EBITDA, or ~18–22x a ~$5+ adjusted EPS), with a genuine accumulation zone below ~$75 and a recession downside toward the mid-$50s/low-$60s if the consumer rolls over at 3.5x leverage. Conviction: medium. What I weigh against myself: the entire RevPAR base is the fragile low-income US consumer late-cycle; not one insider bought at the low and the company repurchased stock at $85.73 — above today’s price; and the leverage (3.5x, ~$1.7B floating) amplifies a relapse. The tag: a $4.58 business hiding behind a $2.50 headline — pay the fair price for the compounding, and the recovery is the free option.

1. Executive Summary

Wyndham Hotels & Resorts is the world’s largest hotel franchisor by property count — ~9,300 hotels, ~846,700 rooms, 25 brands, ~95 countries, ~6,200 franchisees, with 56% of rooms in the United States — and, like Marriott, Hilton, and its closest peer Choice, the defining structural fact is that it owns essentially no hotels. Wyndham licenses brands such as Super 8, Days Inn, La Quinta, Ramada, Microtel, Howard Johnson, Travelodge, Baymont, and Wingate to independent owners in exchange for royalties, and increasingly for high-margin ancillary fees (the Wyndham Rewards co-brand credit card, license/trademark fees). Spun out of Wyndham Worldwide in June 2018, it is the purest economy-and-midscale play among the scaled franchisors — the “everyday traveler” select-service segment.

The economic engine is high-quality and growing, but the GAAP income statement disguises it. FY2025 GAAP revenue of $1,429M decomposes into $541M of royalties & franchise fees, $317M of fast-growing ancillary fees (the RevPAR-insensitive quality layer, up ~59% in four years), $562M of break-even marketing/reservation/loyalty fund pass-through, and small management/other lines. The real fee business throws an ~50% Adjusted EBITDA margin (the Hotel Franchising segment alone runs ~55%). And — critically — it kept growing through a soft RevPAR year: Adjusted EBITDA rose to $718M (+4% comparable) and adjusted diluted EPS to $4.58 (+6%) in 2025, even as global RevPAR fell ~3%. Net unit growth was +4% off a record development pipeline (>259,000 rooms / >2,200 hotels, up 23 consecutive quarters), with 72,000 organic room openings (the most in company history) and 870 signings.

So why did the stock de-rate ~28%? Two reasons, one real and one optical. The real one: RevPAR — Wyndham’s royalty base is the low-income US consumer, and 2025 was a down year (US RevPAR −4%, Q4 the trough at ~−8%), stoking fears of a structural demand problem. The optical one: GAAP diluted EPS collapsed to $2.50 from $3.61, which makes the stock screen at a 31x trailing P/E that looks absurd for a cyclical. But that collapse is almost entirely a single, non-cash, non-recurring credit event — the insolvency of Revo, a European franchisee behind the Vienna House brand, which forced ~$160M of pretax charges (an $86M impairment plus a $74M loss provision on receivables and loans). Normalize it out and earnings grew. The $2.50 print is a Revo-distorted trough, not deterioration — and the company’s Adjusted EBITDA series ($590M → $650M → $659M → $694M → $718M, 2021–2025) shows the clean, steady compounding the GAAP line buries.

Wyndham is the better-executing sibling of Choice, and the contrast is instructive. Both are economy/midscale asset-light franchisors that have shrunk their share counts ~18–22% via debt-funded buybacks and run ~3.5x leverage with thin/negative tangible equity. But where Choice’s legacy core is net-deflagging (US units −141 in 2025), Wyndham’s net unit growth is positive (+4%); where Choice faces a franchisee revolt (the AAHOA endorsement withdrawal, the Highmark procurement arbitration), Wyndham cites best-in-class >94% economy retention; where Choice is controlled ~43% by the Bainum family, Wyndham has a clean institutional shareholder base; and Wyndham was the defender — and operational victor — in Choice’s failed 2023–24 hostile ~$90/share bid. The market rewards this with a modest, justified ~13–22% valuation premium to Choice, and a wide (mostly deserved) discount to the premium-tier compounders Marriott and Hilton (~33–41x P/E, ~21–27x EV/EBITDA, at the rich end of their histories).

The investable tension is whether the Q1-2026 RevPAR inflection (US RevPAR Jan −4% → Feb/Mar/Apr +1%) is the start of a real economy-consumer recovery — in which case a ~11.3x forward EV/EBITDA multiple is pricing a structurally-improving franchisor as a tired cyclical and the recovery is free option value — or a comp-driven head-fake atop a fragile, ~2.5-week-booking-window consumer that relapses into a levered equity. The body that follows argues both sides on the evidence, but the spine is the quality-of-earnings finding: this is a compounding fee machine whose GAAP optics, not its economics, did the damage.

2. Business Overview

What Wyndham does. Wyndham is a pure-play lodging franchisor. It licenses 25 brands and the supporting demand infrastructure — the Wyndham Rewards loyalty program (124M members), central reservations, the marketing fund, revenue-management and now AI-enabled tools (Wyndham Connect/Connect+) — to ~6,200 independent owners, in exchange for (i) a royalty (typically ~5% of the hotel’s gross room revenue), (ii) marketing/reservation/loyalty fund contributions (pass-through, designed to break even), and (iii) a growing stack of ancillary fees. It owns almost no real estate (it briefly consolidated two foreclosed Revo hotels in 2026), carries none of the labor or operating cyclicality of the hotels under its flags, and reinvests for growth chiefly through development advances (“key money”) paid to franchisees to win signings — the asset-light analog of capex.

The brand portfolio is downmarket and broad. Wyndham’s mass is in economy and midscale select-service — Super 8, Days Inn, Travelodge, Microtel, Howard Johnson, Ramada, Baymont, AmericInn, Wingate, La Quinta — serving the “everyday traveler.” Above that sit upper-midscale/upscale (Wyndham, Wyndham Grand, Dolce, Trademark Collection) and a strategically important and fast-growing extended-stay tier (Hawthorn, WaterWalk, and the new-build ECHO Suites prototype). This positioning is deliberately defensive: economy/midscale is where travelers “trade down” in a downturn, which lends Wyndham’s fee base a counter-cyclical cushion that the premium chains lack — at the cost of lower absolute RevPAR and weaker pricing power (see Industry Dynamics).

Two segments, one economic engine. Wyndham reports (i) Hotel Franchising — the ~95%+ economic core — and (ii) a small, declining Hotel Management segment. The Hotel Franchising segment generated ~$781M of Adjusted EBITDA in 2025 (~55% margin), against a ~−$63M corporate overhead drag, for ~$718M consolidated.

The revenue stack (FY2025, from the 10-K revenue note and selected data):

Reading the stack correctly. As with every asset-light franchisor, the ~$1.4B GAAP top line is misleading: a large slice (the $562M marketing/reservation/loyalty fund) is break-even pass-through. The economic fee business is royalties ($541M) plus ancillary ($317M) — ~$858M of high-margin recurring fees. The single most important trend in the stack is ancillary, up ~59% in four years (+15% in FY25, +21% in Q1-2026, credit-card-led) — a genuine quality upgrade that is RevPAR-insensitive and high-margin, the same structural improvement Marriott and Hilton enjoy from their Amex/Chase card licensing and that Choice is chasing through “partnership” fees. Ancillary is now ~37% of the royalty-plus-ancillary fee core and is the lever that let earnings grow on a down-RevPAR year.

FeePAR — the signature unit-economics metric. Wyndham frames its per-unit economics as FeePAR = RevPAR × effective royalty rate. The point: even when RevPAR is flat or down, system FeePAR can rise if (a) the royalty rate ticks up (it did, +7bp in FY25), and (b) newer, higher-fee hotels replace older, lower-fee ones. Wyndham’s record pipeline carries a ~30% domestic / ~20% international FeePAR premium to the existing system, and 85% of the US pipeline is in extended-stay/midscale/upscale/luxury (higher-fee than the legacy economy core). This is the clearest, most durable organic earnings-power lever, and it is structural, not cyclical.

Recurring vs. cyclical. Royalties are contractual and annuity-like (10–20-year agreements, anniversary-only termination, liquidated damages) but applied to a cyclical base (room revenue). Ancillary fees are recurring and RevPAR-insensitive. The marketing fund is break-even. Verdict: a high-quality, capital-light, recurring fee engine — ~$858M of economic fees, ~50% Adjusted EBITDA margin — whose cyclicality runs through the royalty line but is increasingly cushioned by ancillary growth and FeePAR up-mix.

3. Industry Dynamics

Structure: the attractive franchisor tier of a cyclical industry. Branded asset-light lodging is a concentrated oligopoly at the franchisor level — Marriott (~1.7M+ rooms), Hilton (~1.35M), IHG, Wyndham (~847k), Choice (~657k), Hyatt, Accor, plus China’s H World and Jin Jiang. The structural attraction, identical across the cohort, is the profit-pool split: the franchisor takes a high-margin, capital-light royalty while the owner bears the real-estate capital, the labor inflation, and the operating cyclicality. Wyndham sits firmly on the attractive side of that split, and is the #1 player by property count (a function of its economy skew — many small hotels).

Wyndham’s slice: the economy/midscale tier — best-in-tier, but a B-tier slice. As with Choice, Wyndham’s center of gravity is the economy and midscale chain scales, which is structurally inferior to Marriott/Hilton’s premium slice on three axes:

1. Lower ADR → fewer royalty dollars per room. The same ~5% royalty on a $60–95 economy/midscale room yields a fraction of the royalty dollars of a 5% rate on a $200+ upscale room. Wyndham must run many more hotels to earn comparable fees, which is exactly why it leads by count but is mid-pack by rooms and well behind on fee dollars.
2. More cyclical, more exposed demand. Economy/midscale RevPAR is the low-income leisure and value-business traveler — the cohort most pressured by inflation and a softening labor market. This drove the FY2025 RevPAR decline (US −4%).
3. Weaker customer captivity (developed in the Competitive Position section) — at the economy tier, OTAs dominate distribution and guests are price-led.

The defensive counter — trade-down and conversion. The flip side is genuine: economy/midscale is the most downturn-defensive lodging tier (travelers trade down in recessions), and Wyndham’s model is heavily conversion- and small-format-driven, which means it can grow units in both up and down cycles with less dependence on construction financing than the premium chains. The defensive character is real and is why Wyndham’s fee base held up far better than its RevPAR in 2025.

Marathon capital-cycle read. US economy/midscale new construction is muted (high rates suppress new-build economics), which on Marathon’s supply-side logic is constructive for incumbent RevPAR/pricing when demand normalizes — a tailwind for Wyndham’s existing system. Wyndham is also making a deliberate, counter-cyclical new-build bet with ECHO Suites (economy extended-stay), where it argues demand outstrips supply ~3x; this is the one place it is adding supply into a tight market, financed by developers and therefore rate-sensitive. The capital cycle within the franchise tier is intensifying — Wyndham, Choice, Sonesta, G6, and BWH all compete for the same conversions, which is pushing up key money — but Wyndham’s positive NUG and rising royalty rate suggest it is currently winning more than its share.

International — a genuine growth and FeePAR engine. Unlike Choice (~85% US), Wyndham has a meaningful and faster-growing international footprint (Q1-2026 international net rooms +9%: EMEA +7%, LatAm/Caribbean +12%, SE Asia/Pacific +11%, China +13%). The strategically important move is China’s pivot from master-license agreements (MLAs) to direct franchising at ~3x the royalty rate — the direct system has roughly doubled since the spin to ~100,000 rooms. International NUG plus this royalty-rate mix-up is a real, structural FeePAR tailwind that partly offsets soft US RevPAR.

Regulation/structural risk. The same franchise-model exposures apply industry-wide — franchisor vicarious-liability risk and franchisee-relations dynamics — but Wyndham carries less of this heat than Choice (no organized franchisee-association endorsement withdrawal, no high-profile procurement arbitration). Its idiosyncratic structural exposures are the legacy separation agreements with former parent Wyndham Worldwide / Travel + Leisure and concentration in a few large master-license relationships (notably Super 8 in China), both of which are diminishing.

Verdict: Structurally good industry (the franchisor profit-pool split is durable and attractive). Wyndham occupies a B-tier slice but is best-in-tier within it — the economy/midscale skew caps pricing power and royalty-dollars-per-room versus Marriott/Hilton, but Wyndham executes that slice better than Choice, with a real international and FeePAR-mix growth engine layered on top.

4. Competitive Position

Name the moat. In Greenwald’s taxonomy, Wyndham’s advantage is the familiar franchisor combination — (a) economies of scale, (b) customer captivity via loyalty and switching costs, and © a brand intangible — with the franchisee switching-cost leg the strongest and most durable. The honest framing: it is a real but narrow moat, weaker than Marriott’s/Hilton’s on captivity but, unlike Choice’s, not eroding.

Leg 1 — Scale economies (tier-leading, sub-scale vs. the premium pair). Wyndham leads the economy/midscale tier by both hotel count (#1 overall) and tier rooms (~847k vs. Choice’s ~657k), giving it genuine procurement/vendor bargaining power and the ability to spread reservation/technology/marketing fixed costs across the largest economy system. But it is sub-scale versus Hilton (~1.35M rooms) and Marriott (~1.7M+), and far behind them in fee dollars because of the ADR gap. Scale is real and relative; against the premium chains Wyndham is the smaller network.

Leg 2 — Customer captivity / loyalty (the decisive gap, but improving). Wyndham Rewards reached 124M members with a record 54% domestic occupancy contribution from direct/loyalty channels — both real and improving. But set against Hilton Honors (~243M, 80%+ direct) and Marriott Bonvoy (~200M+), Wyndham’s program is roughly half the size, and it operates at the economy tier where OTAs (Expedia, Booking) dominate distribution and guests are price-led. Wyndham’s direct-booking captivity is structurally thinner than the premium pair’s — a genuine quality gap. It is countering with the rising 54% direct contribution, an industry-first debit-card launch, and AI/LLM direct-booking initiatives (Wyndham Connect/Connect+, integrations with Anthropic’s Claude, ChatGPT, and Google’s AI mode), but these are early (~1,100 of ~8,000 US hotels live on Connect+) and unproven at scale.

Leg 3 — Franchisee switching costs (the strongest leg, and not eroding). Wyndham’s most durable advantage is contractual: 10–20-year franchise agreements with anniversary-only termination windows, liquidated damages, and high re-flag costs (signage, systems, property-improvement plans). This is the source of the annuity-like royalty. Crucially, retention is best-in-class — Wyndham cites >94% economy retention — and there is no evidence of the franchisee alienation that plagues Choice (no AAHOA endorsement withdrawal, no procurement arbitration). The franchisee — the franchisor’s real customer — appears, on the evidence, broadly satisfied.

The pricing-power tell. The cleanest read on moat health is the combination of a rising royalty rate (+7bp in FY25), a record pipeline carrying a ~30% FeePAR premium, and the China MLA→direct pivot at ~3x the royalty — all of which signal genuine, if glacial, pricing power and an improving value proposition. This is the opposite of an eroding moat.

Head-to-head vs. Choice (the right comp). Wyndham is the better operator of the two economy/midscale franchisors. Positive net unit growth (+4% in FY25, guided +4–4.5%) versus Choice’s negative US NUG (−141 hotels, −2.2%); cleaner franchisee relations; a record 23-quarter pipeline versus Choice’s legacy-core runoff; and it was the defender and operational victor in Choice’s failed hostile bid. On the evidence, Wyndham is running the shared economy/midscale playbook more effectively — which is the core justification for its modest valuation premium (see Valuation).

The takeover episode as a value test. Choice’s 2023–24 hostile ~$90/share cash-and-stock bid is, in effect, a third-party validation of Wyndham’s standalone value. Wyndham’s board rejected it on price, antitrust, and value-destruction-for-WH-holders grounds, and was vindicated operationally (superior NUG/pipeline/ancillary trajectory). The awkward coda: the stock now trades ~$79, below the rejected ~$90 — so holders who wanted the premium exit were denied one the market has not since restored. With no controlling family, the defense was a board-on-merits decision, but the same absence of a blocking holder makes Wyndham structurally takeover-able.

Verdict: A durable but narrow moat — strongest on franchisee switching costs and economy/midscale scale leadership, weaker on loyalty/direct-booking captivity than Marriott/Hilton, but not eroding. Positive NUG, rising royalty rate, >94% retention, and a growing FeePAR premium all confirm the value proposition is improving. Best operator in a B-tier slice; a real moat, just not a premium-grade one.

5. Growth History and Forward Opportunities

Net unit growth is positive and organic — the headline contrast with Choice. Wyndham grew global net rooms +4% in FY2025, with FY2026 guided to +4–4.5%, and Q1-2026 ran +4% (international +9%, domestic roughly flat on one-time legacy-affiliate exits — ~3,000 rooms from Travel + Leisure / Vacasa Wyndham Vacation Resorts closures and a 17-resort optimization). This is organic, not acquired: FY2025 saw a record 72,000 organic room openings (+13% YoY, ~600 hotels) — the most in company history — with new-construction openings +50% domestically, and 870 signings (+18%). The development pipeline is at a record >259,000 rooms / >2,200 hotels, up 23 consecutive quarters, with the domestic share now >43% of the total (up from ~33% at the 2018 spin). That Wyndham grew units through a RevPAR downcycle, while Choice’s legacy core deflagged, is the single sharpest fundamental distinction between the two.

RevPAR — the cyclical headwind, now inflecting. Global RevPAR fell ~3% in FY2025 (US −4%; China −9%), with Q4-2025 the trough (domestic ~−8%, the hurricane-hit and large states TX/CA/FL down ~11%). Q1-2026 inflected sharply: US RevPAR moved from Jan −4% to Feb/Mar +1%, global RevPAR improved ~450bp sequentially, and domestic (ex-hurricane) came in roughly flat against a guided −2% to −3%; April tracked consistent with Feb/March. Management raised the FY2026 global RevPAR guide to +1% to −1% while holding the back half “approximately flat” pending peak-summer visibility — appropriately cautious given a ~2.5-week booking window. The recovery has a long runway in theory: economy ADR is only ~+11% versus 2019, against ~+25–26% cumulative inflation and ~+30% for luxury — a real catch-up gap if the consumer stabilizes.

The FeePAR / mix-up engine. Beyond units, Wyndham’s per-room economics are improving structurally: the royalty rate is rising (+7bp FY25), the pipeline carries a ~30% domestic FeePAR premium, 85% of the US pipeline is in higher-fee tiers, and the China direct-franchising pivot lifts realized royalty ~3x on converted rooms. System FeePAR ratchets up via mix even at flat RevPAR — the clearest organic earnings-power lever and the reason adjusted EBITDA can grow on a down-RevPAR year.

Ancillary — the highest-quality growth vector. Ancillary revenue grew +15% in FY2025 and +21% in Q1-2026 (lapping the renewed Barclays co-brand credit-card economics signed March 2025), guided to low-to-mid-teens for FY2026 and high-single-digit long term. This is the RevPAR-insensitive, high-margin layer — it diversifies the fee base away from room-revenue cyclicality and is, dollar-for-dollar, the best growth Wyndham has.

ECHO Suites and extended stay. The new-build economy extended-stay prototype reached 20 open hotels (7 in the prior six months) with a record ~45,000-room extended-stay pipeline (+4% YoY). Management asserts ECHO unit-level RevPAR and margins are “ramping in line with expectations” — a claim with no external verification yet, and small in absolute room terms today, but a credible multi-year domestic NUG engine in a segment where demand reportedly outstrips supply ~3x. It is development-financing-dependent and therefore rate-sensitive.

Quality of growth. High and largely organic. The growth is multi-vector — units (record openings, 23-quarter pipeline) + royalty rate + FeePAR mix-up + RevPAR-insensitive ancillary — and it is real per-room and per-unit, not merely buyback optics. The proof is that comparable Adjusted EBITDA grew +4% and adjusted EPS +6% in FY2025 despite −3% RevPAR, with Q1-2026 segment Adjusted EBITDA +8% — model resilience confirmed. Buybacks (~18–22% share-count reduction since the spin) flatter per-share figures, but the underlying fee engine is genuinely growing, which is the opposite of the “growth manufactured per-share faster than earned per-unit” verdict I reached on Choice. Verdict: high-quality, organic, multi-vector growth — best-in-tier — though it rides a cyclical RevPAR base now inflecting up, and the ECHO ramp economics remain management-asserted.

6. Financial Quality

The central quality-of-earnings question — answered. A screen sees GAAP diluted EPS collapse from $3.61 (2024) to $2.50 (2025) and a 31x trailing P/E, and concludes Wyndham is an expensive, deteriorating cyclical. That is wrong, and resolving it is the spine of the entire thesis. The FY2025 GAAP drop (net income $193M vs. $289M; operating income $509M vs. $558M; pretax $263M vs. $368M) is almost entirely a single, identifiable, non-cash, non-recurring credit event: the insolvency of Revo, a large European franchisee behind the Vienna House brand. The 10-K MD&A bridge shows total expenses +$114M, driven by:

• +$74M loss provision on accounts and loans receivable from Revo;
• +$74M higher impairment ($86M in FY25 — the Vienna House trademark, related franchise agreements, and development-advance notes — vs. $12M in FY24), also Revo-driven;
• +$12M separation-related (FY24 carried a one-time spin-reserve-reversal benefit) and +$3M restructuring;
• partially offset by −$45M lower transaction costs as the 2024 Choice takeover-defense expense rolled off.

So Revo alone = ~$160M of FY2025 pretax charges, entirely non-cash/non-recurring. (The effective tax rate also rose to 26.6% from an artificially-low 21.5% in FY24 — but FY24 was the anomaly, flattered by Puerto Rico credits and the non-taxable separation reversal; 26.6% is the normalized rate, not a penalty.)

True earnings power grew. The GAAP-to-adjusted bridge reconciles net income of $193M up to Adjusted EBITDA of $718M (+4% comparable) via the standard add-backs (tax, D&A, net interest, SBC $41M, development-advance-note amortization $32M) plus the one-time Revo impairment $86M and provision $74M and restructuring $18M. Adjusted diluted EPS was $4.58 (+6% comparable) — and a clean cross-check ties it: $2.50 GAAP + ~$117M after-tax Revo ($160M × (1−0.266)) + ~$15M after-tax restructuring/transaction ≈ ~$354M adjusted net income ÷ 77.2M shares ≈ $4.58. True normalized EPS is ~$4.55–4.60, not $2.50. The clean run-rate is the Adjusted EBITDA series — $590M (2021) → $650M → $659M → $694M → $718M (2025) — steady ~4–9%/yr compounding, against noisy GAAP net income ($244M / $355M / $289M / $289M / $193M). Quality of earnings is high; the GAAP collapse is a clean one-off, not margin erosion, accounting aggression, or a demand cliff.

One honest caution on the QoE. Revo-type franchisee-credit losses are a recurring-in-kind risk of the key-money/development-advance growth model — “non-recurring” credit charges will recur episodically as a cost of buying growth. FY2025’s magnitude is a genuine outlier (management cites ~$20M of residual loan exposure across all other franchisees, with no single one >~5% of the development-advance balance), but it is a structural feature, not a true one-time-and-gone event.

Fee margins and returns. On ~$858M of economic fee revenue (royalties + ancillary), the $718M consolidated Adjusted EBITDA implies an ~50% margin (the Hotel Franchising segment ~55%), and Q1-2026 segment Adjusted EBITDA grew +8% on +3% revenue — clear operating leverage. ROIC was 12.1% in FY2025 (Revo-depressed) and ~14.4% in FY2024 — normalized ~14–15% — solid but not spectacular, the economy-tier “worse slice” point again (fewer fee dollars per room than Marriott/Hilton). ROE (34%) and P/B (13.5x) are meaningless — equity is a buyback-eroded residual (~$468M, with negative tangible book of ~−$33/share, since goodwill + intangibles of ~$3B dwarf equity). Anchor on EV/EBITDA, P/adjusted-EPS, and FCF yield.

Free cash flow. FY2025 operating cash flow was $367M against just $46M of capex (asset-light), for ~$321M of simple FCF; the company cites ~$433M of “adjusted free cash flow” (~60% conversion from Adjusted EBITDA). The honest haircut: rising development-advance amortization ($32M, added back to Adjusted EBITDA) was prior cash out, and the development-advance balance grew ~$35M (to $343M), so true owner cash is ~$30–50M/yr below the headline. Still, FCF yield is a healthy ~8% on the de-rated equity — supportive of the valuation.

Balance sheet — moderate, managed risk. Total debt is $2,563M against $64M cash → net debt ~$2,496M, or ~3.5x net Adjusted EBITDA (4.4x on GAAP EBITDA). The structure is well-laddered and now largely fixed after a February-2026 $650M senior-notes issuance (5.625%) that termed out maturities: Term Loan B $1.5B/2030, Term Loan A $337M/2027, $500M notes/2028, the new $650M notes, and a $1.0B revolver/2030, with ~$1.1B liquidity and a 2.8x first-lien leverage well inside covenants. The real flags are (1) negative tangible equity — the capital structure is levered to a perpetual buyback with no equity cushion — and (2) ~$1.7B of floating-rate debt in a higher-for-longer world (interest expense rose ~$15M in FY25). This is the asset-light playbook (the same as Choice and Hilton), financed aggressively but not recklessly; it is not distress, but it amplifies a RevPAR relapse.

Verdict: Economics hold and modestly improve with scale (stable ~50% Adjusted EBITDA margin, positive operating leverage, FeePAR mix-up, ~14–15% normalized ROIC). Quality of earnings is high — the FY2025 GAAP collapse is a clean, non-cash Revo one-off, and true earnings grew. The balance sheet is a moderate, managed risk (3.5x leverage, well-laddered, ample liquidity), with negative tangible equity and floating-rate exposure the genuine watch items.

7. Capital Allocation

Wyndham’s management is a competent, shareholder-oriented allocator with two yellow flags — better-governed than Choice (no controlling family), but with a buyback discipline question and a key-money credit-risk tail.

Thread 1 — The Choice takeover defense (a vindicated, costly call). Wyndham was the target of Choice’s 2023–24 hostile ~$90/share cash-and-stock bid. The board rejected it on price, antitrust, and value-destruction grounds, and the direct cost was ~$47M of transaction expense in FY2024 (~16c/share, one-time). The defense was vindicated operationally — Wyndham’s standalone NUG/pipeline/ancillary trajectory has outperformed — but the shareholder coda is awkward: the stock now trades ~$79, below the rejected ~$90, so holders who wanted the premium exit were denied one the market hasn’t restored. With no controlling family, this was a board-on-merits decision; whether it maximized shareholder value depends entirely on whether the standalone compounding eventually clears ~$90 (the base case says yes within ~2 years; the bear says the bid was the high-water mark).

Thread 2 — Buybacks (the discipline question). Diluted shares fell from 93.9M (2021) to 77.2M (2025) — and from ~98M at the 2018 spin — a ~18–22% reduction, via $1.9B of cumulative repurchases at an average ~$69.37. This share-count math is why adjusted EPS grew +6% in FY2025 versus Adjusted EBITDA +4%. But the discipline is questionable: FY2025 repurchases averaged $85.73 — above the current ~$79 and amid a −28% de-rating (Q4-2025 monthly: Oct $78.50, Nov $71.65, Dec $76.47). This was steady, ratable buying, not counter-cyclical value-buying, and it is compounded by an LTI structure (below) that rewards buybacks regardless of price. Returning ~all FCF and growing debt to do so — holding leverage at ~3.5x rather than deleveraging — is financial engineering in service of EPS; it creates value only if shares are bought below intrinsic value, and $85.73 into a de-rating is, charitably, a coin-flip.

Thread 3 — Dividend and total return. The dividend is $1.65/share (raised +8% to $0.41/qtr early-2025, then +5% to $0.43/qtr in Q4-2025), a ~2.1% yield and a comfortable ~36% of adjusted EPS (the ~66% of GAAP EPS is Revo-distorted). Total capital returned in FY2025 was ~$393M ($266M buyback + $127M dividend) — ~110% of simple FCF / ~91% of adjusted FCF — funded partly by ~$93M of incremental net debt. The model returns everything it generates and then some, leaning on the balance sheet to hold leverage flat.

Thread 4 — Development advances / key money. The asset-light growth-capital line grew from $308M (2024) to $343M (2025), with amortization rising ($15M → $24M → $32M). This is cash paid to franchisees to win deals, amortized against royalties and added back to Adjusted EBITDA — and the Revo $160M charge is the downside of that model crystallizing. On Marathon’s lens, Wyndham is deploying growth capital into a muted-new-build economy cycle (supply-side-disciplined if the openings prove durable), with franchisee-credit losses the recurring cost of buying growth.

Compensation and alignment. The annual incentive is 75% Adjusted EBITDA + 25% global net room growth (FY2025 adjusted-EBITDA target $750M vs. $718M actual → below-target payout; NUG target 3.55% vs. ~3.5% actual). The LTI is PSUs vesting on 3-year adjusted EBIT-per-share plus 4-year RSUs and options. The metrics are operationally sensible and aligned, but two soft spots: Adjusted EBITDA is flattered by key-money amortization add-backs, and the EBIT-per-share LTI directly incentivizes buybacks regardless of price with no relative-TSR market gate surfaced — a governance watch item that may explain the buying above fair value. CEO Geoffrey Ballotti owns 832,015 shares (~1.11%).

Governance — the clean contrast with Choice. Wyndham has no controlling family: top holders are pure institutions (Vanguard 11.05%, BlackRock 9.42%, T. Rowe 6.13%), with non-executive Chairman Stephen Holmes (ex-Wyndham Worldwide CEO) holding ~374k shares. This is a genuine quality advantage over Choice’s ~43% Bainum-family control and buyback-as-control-creep dynamic — the board answers to all shareholders. The flip side: no blocking holder makes Wyndham structurally takeover-able (as Choice’s bid demonstrated).

Leadership transition. CFO Michele Allen departed (announced November 2025, “to pursue a new career opportunity outside the hotel industry”), Kurt Albert served interim, and Amit Sripathi — a ~5-year Wyndham veteran from the development/M&A side (Chief Development Officer) — was appointed CFO (effective late-2025/early-2026, first call Q1-2026). Internal promotion with development-side pedigree favors continuity over disruption; modest key-person risk, well-mitigated.

Verdict: Mostly intelligent, two yellow flags. Pluses: asset-light reinvestment at ~14–15% normalized ROIC; rejected a dilutive bid and defended standalone value (vindicated operationally); sensible, aligned comp metrics; clean institutional governance; a well-covered, growing dividend. Minuses: ~$1.9B of buybacks with a meaningful slug bought above the now-de-rated price, debt-funded, with an EBIT/share LTI that rewards buybacks regardless of value; and a key-money model that produces episodic franchisee-credit losses (Revo $160M) the Adjusted EBITDA framing understates. A competent, shareholder-oriented allocator — not a distinguished one. Buyback discipline is the watch item.

8. Changes and Headwinds — Last Two Years

The Choice takeover defense and aftermath (2023–Q1 2024). Covered above. Net: the overhang (distraction, ~$47M defense cost, antitrust scrutiny of the economy/midscale duopoly) is gone, but so is the ~$90 third-party bid floor — the stock has since de-rated to ~$79, leaving a standalone RevPAR-recovery story with no takeout support.

RevPAR deterioration, then a sharp Q1-2026 inflection. FY2025 was a down-RevPAR year (US −4%, China −9%), with Q4-2025 the trough (domestic ~−8%). Q1-2026 inflected: US RevPAR Jan −4% → Feb/Mar/Apr +1%, global +450bp sequentially, domestic ex-hurricane roughly flat against a guided −2/−3%. Management raised the FY2026 global RevPAR guide to +1%/−1% while holding the back half “approximately flat.” This is the swing factor for the equity (see Valuation and Variant Perception).

Mix and ancillary up-shift (structural positives). The record pipeline (23 consecutive quarters of growth), the rising domestic/higher-tier pipeline share (>43% vs. ~33% at spin), the China MLA→direct pivot (~3x royalty), and ancillary +15%/+21% (credit-card-led) are all genuine, structural improvements to earnings power that compounded through the RevPAR trough.

ECHO Suites ramp. 20 hotels open, a record ~45,000-room extended-stay pipeline — the multi-year domestic NUG engine, with management-asserted (unverified) unit economics.

Balance sheet actions. A February-2026 $650M senior-notes issuance (5.625%) repaid the revolver and term-loan and termed out maturities; ~$1.1B liquidity; net leverage 3.5x. The October-2025 revolver amend/extend (to $1.0B/2030, −35bp) was a modest positive.

CFO transition (November 2025). Michele Allen out; Amit Sripathi (internal, development-side) in — continuity over disruption.

Revo insolvency. The defining negative of the period — ~$160M of FY2025 non-cash charges that crushed GAAP EPS to $2.50 (see Financial Quality). Idiosyncratic and contained (~$10M FY26 revenue, ~no earnings impact from the two foreclosed hotels; ~$12M FY royalty-line impact), but a vivid example of the franchisee-credit tail risk in the key-money model.

Net thesis impact. Over two years Wyndham lost a ~$90 takeout bid and de-rated through a RevPAR downcycle, yet the franchise machine kept compounding (record pipeline, +4% NUG, FeePAR up-mix, +22% ancillary, ~22% share-count reduction). On balance the changes are net positive for earnings power (mix, ancillary, NUG, termed-out debt), but the equity story now hinges on a fragile, short-booking-window cyclical recovery against 3.5x leverage.

9. Risk Analysis

The catastrophic-loss question. Low. Wyndham is an asset-light, ~$700M-Adjusted-EBITDA, FCF-generative franchisor with termed-out, mostly-fixed debt and ~$1.1B liquidity. The realistic bad outcome is not a blow-up but a levered de-rating: a deep, prolonged consumer recession that compresses RevPAR and NUG simultaneously against 3.5x leverage, forcing a buyback pause and a multiple grind — painful, not existential. The tail risk that is genuinely hard to underwrite is the same franchisor vicarious-liability dynamic that hangs over the whole industry, plus the recurring-in-kind franchisee-credit losses that Revo just demonstrated.

10. Valuation Discussion

No price target and no recommendation. Embedded-expectations and scenario framing only.

The markers. At ~$79.39 (2026-06-12), with ~77M diluted shares, Wyndham’s market cap is ~$5.8–6.2B and EV ~$8.3–8.5B (net debt ~$2.5B). FY2026 guidance midpoints: revenue ~$1.485B, Adjusted EBITDA ~$737.5M, adjusted net income ~$358M, adjusted diluted EPS ~$4.71.

Multiples — anchor on adjusted, not GAAP. The headline GAAP/TTM P/E of ~31.8x (on the Revo-distorted $2.49 TTM EPS) is meaningless — discount it. On the clean figures:

• Forward EV/Adjusted EBITDA ~11.3x ($8.4B / $737.5M) — below Wyndham’s own 2018–2025 ~12.7–16.5x band.
• Forward P/adjusted-EPS ~16.9x ($4.71).
• FCF yield ~8% (~$500M FCF / ~$5.8–6.2B cap) — supportive.
• P/S ~4.1–4.2x versus Wyndham’s own post-spin range of ~2.4–5.7x.

Own-history context (the clean read). The AZI valuation_index puts Wyndham at the 75.8th percentile composite of its own (short, COVID-spanning, ~7-year) history — but that is distorted: the P/E percentile (78.5th) rides the Revo-trough GAAP EPS, and the P/B percentile (96.4th) rides the buyback-thinned $5.90 book value. The clean, un-distorted read is P/S at the 52.5th percentile — the middle of its own range — and forward EV/EBITDA below its historical band. On the metrics that aren’t artifacts, Wyndham is mid-range-to-cheap on its own history, consistent with a cyclical RevPAR trough, not a froth peak.

Peer cross-read — the bifurcated cohort.

The asset-light cohort is sharply bifurcated: Marriott/Hilton are premium compounders at all-time-rich ~21–27x EV/EBITDA; Wyndham/Choice are economy-tier names in the low-teens. Wyndham trades at a ~13–22% premium to Choice (forward P/E ~16.9x vs. ~15x) and a wide discount to Marriott/Hilton. The premium to Choice is justified and modest — Wyndham has positive NUG (vs. Choice’s negative), cleaner franchisee relations, the ECHO new-build engine, no controlling family, and was the better-executing party in the failed merger. The discount to Marriott/Hilton is largely deserved — they are higher-quality businesses with deeper moats, higher fee dollars per room, and faster NUG; Wyndham is a lower tier, not a cheaper clone.

Embedded expectations / reverse read. At ~11.3x forward EV/Adjusted EBITDA, an ~8% FCF yield, and a ~4% buyback, the market is pricing roughly: NUG continuing ~4–5%/yr (the least-contested assumption — 23 straight quarters of record pipeline make this near-base-rate); RevPAR essentially flat-to-modestly-positive long run (the de-rate from ~$110 to ~$79 has removed the recovery option value from the price); and FeePAR/royalty up-mix plus high-single-digit ancillary growth delivering mid-to-high-single-digit Adjusted-EBITDA growth, with buybacks adding ~3–4%/yr per-share. The embedded total-return math works on flat RevPAR — so a genuine RevPAR recovery (the Q1-2026 inflection holding) is largely un-priced upside. That asymmetry is the heart of the bull case.

Scenarios (explicit assumptions; no price target):

• Bear: A US consumer recession; RevPAR −3% to −5% in FY27; NUG decelerates to ~2–3% as developer financing tightens; ancillary growth halves; Adjusted EBITDA flat-to-down (~$700–720M); the multiple compresses to ~9–10x EV/EBITDA; the buyback is paused to defend 3.5x leverage. Falsifier of the long: RevPAR turns negative again and pipeline conversion stalls.
• Base: RevPAR flat to +1–2%; NUG 4–4.5%; ancillary high-single-digit; FeePAR up-mix; Adjusted EBITDA ~$770–810M by FY27; ~$250M/yr buyback; multiple holds ~11–12x. Per-share earnings compound mid-to-high-single-digit; the ~8% FCF yield + buyback drive returns.
• Bull: The Q1-2026 inflection broadens; RevPAR +3–5% as economy ADR closes its 2019 gap; NUG 4.5–5%+; ECHO/extended-stay accelerates; ancillary low-teens; Adjusted EBITDA $820–860M by FY27; the multiple re-rates toward 13–14x as recovery option value re-prices; strategic-acquirer interest could even re-emerge (the Choice precedent).

Verdict (no rec): On the un-distorted metrics, Wyndham is mid-range-to-cheap on its own history (P/S 52nd percentile, forward EV/EBITDA below its band) with a fair ~17x forward adjusted P/E and an ~8% FCF yield — a justified modest premium to Choice and a deserved discount to Marriott/Hilton. The embedded expectations price approximately no RevPAR recovery, so the asymmetry favors the long if the Q1-2026 inflection proves durable — but the cheapness is fair, not deep, and the call rides the most cyclical, lowest-income consumer cohort at 3.5x leverage.

11. Variant Perception

Consensus belief. Wyndham is a decent asset-light economy/midscale franchisor whose earnings are hostage to a weak low-income consumer; post the failed Choice bid it has de-rated to a “show-me” cyclical at low-teens EV/EBITDA — cheaper than Marriott/Hilton for good reason. Street models flat-ish RevPAR, ~4% NUG, modest EBITDA growth, and a holding-pattern multiple. The GAAP $2.50 EPS reinforces the “stalling cyclical” read.

The strongest bull case. The market is mispricing a structurally-improving franchise machine as a pure RevPAR cyclical. NUG of 4–4.5% + FeePAR up-mix (43% of the pipeline now domestic/higher-tier at a ~30% RevPAR premium) + high-single-digit ancillary + an ~8% FCF yield + a ~22% share-count reduction since the spin compound per-share earnings at mid-to-high-single-digit on flat RevPAR. Any RevPAR recovery — and economy ADR is only +11% vs. 2019 against +25–26% inflation, a real catch-up runway — is near-free option value. At ~11.3x forward EV/EBITDA and P/S at its own 52nd percentile, you are not paying for the recovery. The GAAP $2.50 is a Revo mirage hiding a $4.58 business.

The strongest bear case. Wyndham’s RevPAR base is the low-income US consumer — the most fragile cohort late-cycle. The Q1-2026 inflection rests on a ~2.5-week booking window and easy comps, and management itself holds the back half “approximately flat.” Leverage of 3.5x with rising refinancing cost (the new 5.625% notes) means a RevPAR relapse hits a levered equity and forces a buyback pause. The Choice ~$90 bid floor is gone; negative momentum, negative alpha, and a poor 5-year Sharpe say smart money has already left; and not one insider bought at the low while the company repurchased stock at $85.73 — above today’s price. “Cheap vs. Marriott/Hilton” — but those are better businesses; “cheaper than recovery implies” — but vs. Choice, Wyndham is the more expensive economy name.

The 3–5 assumptions that matter most. (1) Does the Q1-2026 RevPAR inflection hold through peak summer (FIFA, tax refunds, drive-to leisure)? (2) Does NUG stay 4–4.5%+ and does the FeePAR up-mix actually lift realized royalty per room? (3) Does ancillary growth normalize to a sustainable high-single-digit after the credit-card lap, or fade? (4) Is the buyback sustainable at 3.5x leverage if RevPAR relapses? (5) Is the ~13–22% premium to Choice (and discount to Marriott/Hilton) the right relative mark?

Falsification tests. The bull is falsified if 2H-2026 US RevPAR turns negative again and NUG slips below ~3% (the inflection was a comp artifact). The bear is falsified if RevPAR sustains positive into Q3/Q4-2026, FeePAR/ancillary drive Adjusted EBITDA toward/above the high end ($745M+), leverage trends below 3.5x, and the buyback continues — the de-rated cyclical re-rates as a compounder.

The factor-positioning read (evidence, not a price call). Wyndham’s factor signature is a negative-momentum (−0.16), negative-growth/value-tilted (−0.25 to −0.39), modest-quality, small-cap-tilted, rate/credit-sensitive consumer-discretionary travel name — closer to Choice’s “abandoned-value” signature than to Marriott’s/Hilton’s quality-momentum-compounder profile. The risk-adjusted track record is poor over 1–5 years (1-yr return −0.9%/Sharpe −0.10; 5-yr +2.5%/Sharpe ~0.0; max drawdown −37%), which is the quantified embodiment of the bear’s “de-rated cyclical, not a compounder over this window.” But the tape is turning: a +23.5% three-month return (Sortino 1.23) and rs_6m +9.2% mark a nascent momentum reversal off the trough (the RevPAR inflection showing up in price), beta ~0.92, alpha −0.14. Factor-similar peers are Marriott (0.98), Hilton (0.95), Hyatt, Choice (0.93), TNL, and IHG — validating the lodging-franchisor comp set. Net: consensus is positioned as if Wyndham is structurally-impaired value / a falling knife, while the freshest tape disagrees — empirical support for the variant that the recovery option value of a still-compounding franchise machine is under-priced. The factor read identifies the setup; it does not adjudicate whether the turn is durable — only the RevPAR/NUG prints can.

12. Fact vs. Interpretation

13. Open Questions

1. Does the Q1-2026 RevPAR inflection hold through peak summer? Management deliberately held the back half “approximately flat”; the ~2.5-week booking window means visibility is short. The Q2/Q3-2026 prints are the decisive test.
2. Does the FeePAR up-mix translate into rising realized royalty per room, or does legacy economy churn offset the higher-fee pipeline?
3. Does ancillary growth normalize to a sustainable high-single-digit after the Barclays credit-card lap, or fade faster?
4. What is the exact, full residual franchisee-credit exposure beyond Revo (management cites ~$20M) as the development-advance balance keeps climbing?
5. Will the buyback continue at 3.5x leverage if RevPAR relapses, and does the EBIT-per-share LTI keep driving repurchases above fair value?
6. What is the company’s precise “adjusted FCF” definition ($433M vs. $321M simple FCF — a $112M gap that overstates owner cash)?
7. Does a strategic acquirer re-emerge now that the antitrust-fraught Choice combination is dead and the stock trades below the rejected ~$90?

14. What Must Be True

For the bull case (de-rated compounder re-rates):

1. The Q1-2026 RevPAR inflection holds into peak summer and beyond — positive US RevPAR sustained for 2+ quarters. Falsification: 2H-2026 US RevPAR turns negative again.
2. NUG stays 4–4.5%+ as the record pipeline converts and ECHO/extended-stay ramps. Falsification: NUG slips below ~3%.
3. FeePAR up-mix + ancillary drive mid-to-high-single-digit Adjusted-EBITDA growth on flat RevPAR, proving the model compounds without a demand tailwind. Falsification: Adjusted EBITDA flat-to-down on flat RevPAR.
4. The buyback continues on cheap-ish equity and leverage trends toward/below 3.5x — per-share compounding plus a re-rating. Falsification: buyback paused to defend leverage.
5. The multiple re-rates toward 12–14x EV/EBITDA as the recovery option re-prices. Falsification: the de-rating persists on growing adjusted earnings.

For the bear case (levered cyclical, value trap):

1. The RevPAR weakness is structural, not cyclical — the low-income consumer stays pressured and the inflection was a comp artifact. Falsification: ADR-led RevPAR growth resumes.
2. NUG decelerates as developer financing tightens and economy franchisee economics deteriorate. Falsification: NUG holds 4%+.
3. Leverage + the fragile consumer force a buyback pause in a relapse, removing the per-share crutch. Falsification: buyback sustained through a soft patch.
4. Key-money franchisee-credit losses recur at scale (the next Revo), eroding the asset-light returns. Falsification: credit losses stay idiosyncratic and small.
5. The market correctly prices a B-tier economy name that deserves its discount to Marriott/Hilton and offers no edge over Choice. Falsification: a sustained re-rate as a quality compounder.

The clean feature of Wyndham, as with Choice, is that both falsification sets are testable within two-to-three quarters — the RevPAR and NUG prints of mid-to-late 2026 will resolve the cyclical-trough-versus-structural-impairment debate.

15. Source Appendix

See Appendix B below for the full source list with dates and EDGAR/transcript references.

The body of this memo (the main analysis) takes no position and contains no price target by design; the sole exception is the clearly-labeled “Claude’s Take” block at the top, which is the author’s own subjective opinion.

APPENDIX A — Standard Diligence Questionnaire

Wyndham Hotels & Resorts, Inc. (NYSE: WH) — Diligence Appendix Report date: 2026-06-13 · Supplemental to the research memo (not counted toward the memo length standard). Fact / Interpretation / Assumption labels applied where it matters.

General

What thoughtful questions have other investors asked about this company? The dominant question is whether Wyndham is a structurally-improving compounder mispriced as a tired cyclical, or a levered bet on the fragile low-income consumer at a fair-not-cheap multiple. Sub-questions: (1) Why did GAAP EPS collapse to $2.50 — is the business deteriorating? (Fact: no — it’s the one-time ~$160M Revo insolvency charge; adjusted EPS was $4.58, +6%.) (2) Is the Q1-2026 RevPAR inflection real or a comp head-fake? (3) Can the franchise machine keep compounding (NUG + FeePAR + ancillary + buyback) on flat RevPAR? (Fact: it did in 2025 — adj EBITDA +4% on −3% RevPAR.) (4) Is the ~3.5x leverage + buyback-above-price prudent? (5) Is WH’s premium to Choice and discount to Marriott/Hilton the right relative mark? The failed Choice bid (~$90) and the subsequent de-rate to ~$79 frame much of the debate.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? (Interpretation:) Closer to a cyclical low. FY2025 was a down-RevPAR year (US −4%, China −9%), Q4-2025 the trough (domestic ~−8%); Q1-2026 inflected positive. Adjusted earnings are near a cyclical trough on the RevPAR axis, partly offset by structural NUG/FeePAR/ancillary growth.

Driven by external environment or internal actions? Both. External: soft economy/midscale RevPAR, the pressured low-income consumer, China ADR deflation. Internal: the structural FeePAR up-mix, ancillary/credit-card growth, the China direct-franchising pivot, ECHO Suites, and debt-funded buybacks.

How stable are revenues? The fee core is highly stable (contractual royalties on ~9,300 hotels, 10–20-yr agreements, liquidated damages, >94% retention), with a fast-growing RevPAR-insensitive ancillary layer — but royalties are levered to a cyclical room-revenue base.

Outlook for products/services? Constructive: positive NUG (+4%, guided +4–4.5%), record pipeline (23 consecutive quarters), ECHO/extended-stay growth, and double-digit ancillary growth, against a cyclical-but-inflecting RevPAR base.

How big is this market — growing/shrinking, domestic/international? US lodging is large and mature; the economy/midscale slice is low-growth and cyclical. Unlike Choice, Wyndham has a meaningful, faster-growing international footprint (44% of rooms outside the US; Q1-2026 international rooms +9%), plus the China MLA→direct royalty up-shift.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? (Interpretation:) More competitive at the conversion tier — Wyndham, Choice, Sonesta, G6, and BWH compete for the same economy/midscale conversions, pushing up key money. Wyndham is currently winning more than its share (positive NUG, rising royalty rate).

How profitable is the business (ROIC, ROE)? (Fact:) ROIC ~12.1% (FY2025, Revo-depressed), ~14.4% (FY2024); normalized ~14–15% — solid but below Marriott/Hilton (fewer fee dollars per room). ROE (34%) and P/B (13.5x) are meaningless (buyback-eroded equity; negative tangible book). Use ROIC.

How profitable is the industry — competitors, barriers to entry? The franchisor tier is very profitable (capital-light royalty annuities). Barriers: brand, loyalty network, distribution scale, 10–20-yr contracts. (Interpretation:) Wyndham’s barriers are tier-leading but narrower than the premium chains’ — smaller, OTA-reliant economy-tier loyalty.

Can the business be easily understood? Yes — a royalty-on-room-revenue model, with the wrinkle of reading through the marketing-fund pass-through and the Revo-distorted GAAP to the ~$858M fee core.

Can it be undermined by foreign low-cost labor? No — domestic/local, real-estate-anchored.

Do brands matter? Yes, but less at the economy tier (price-led, OTA-routed) than upmarket. The rising royalty rate and FeePAR premium are the pricing-power tells; Wyndham Rewards (124M members, 54% direct) is the captivity asset.

Nature of competition? For guests: brand, price, location, loyalty, OTA placement. For franchisees (the real competition): the ROI a flag delivers and the total fee load — where Wyndham’s >94% retention says its value proposition holds (the contrast with Choice’s AAHOA friction).

Customers’ switching costs? (Fact:) High — 10–20-yr contracts, liquidated damages, re-flag/PIP costs. Wyndham’s strongest, most durable moat leg.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Yes — the brands, Wyndham Rewards network, and franchise relationships are not capitalized (organic brand value carries no balance-sheet line), which is why equity is thin/negative-tangible and P/B is meaningless. Economic value sits in the off-balance-sheet fee annuity.

Off-balance-sheet liabilities? Operating leases (modest), development-advance/key-money commitments, separation/tax-matters indemnities to former parent (Travel + Leisure), and contingent franchisee-credit exposure (Revo demonstrated the risk).

How conservative is the accounting? (Interpretation:) Clean. The marketing fund is run ~breakeven; the GAAP-to-adjusted bridge is transparent; the Revo charge was taken promptly and fully. The one caution: Adjusted EBITDA adds back development-advance-note amortization (prior cash out), modestly flattering “adjusted” cash economics.

How CapEx-hungry is the business? Genuinely capital-light (~$46M PP&E capex); the real growth capital is development advances/key money ($343M balance, +$35M/yr), the asset-light analog of capex — and the source of episodic franchisee-credit losses.

Capital Allocation & Management

How much FCF does it generate, how is it used, what’s the philosophy? (Fact:) OCF ~$367M, simple FCF ~$321M, company adjusted FCF ~$433M (~60% conversion). Philosophy: invest in development advances, then return ~all FCF (and a bit more, via debt) through dividends and buybacks, holding leverage ~3.5x.

Significant acquisitions recently? No major M&A; Wyndham was the target (not acquirer) in Choice’s failed 2023–24 hostile bid. Growth is organic.

Buying back shares? Yes — ~18–22% of the count since the 2018 spin ($1.9B at ~$69.37 avg). But FY2025 repurchases averaged $85.73 — above the current ~$79 — a discipline yellow flag, debt-funded, and incentivized by an EBIT-per-share LTI.

Issuing large amounts of new shares to insiders? No — share count is falling; SBC is modest (~$41M).

Compensation policy of directors/management? (Fact:) Annual incentive 75% Adjusted EBITDA + 25% net room growth; LTI = 3-year adjusted EBIT-per-share PSUs + RSUs + options. Operationally sensible, but the EBIT-per-share metric rewards buybacks regardless of price (no relative-TSR gate surfaced).

Motivations of management? CEO Geoffrey Ballotti (long-tenured, ~1.11% ownership) and new internally-promoted CFO Amit Sripathi. No controlling family (Vanguard 11%, BlackRock 9.4%, T. Rowe 6.1%) — a genuine governance advantage over Choice’s ~43% Bainum control; the board answers to all shareholders (and the company is structurally takeover-able).

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? No — a US domestic C-corp (NYSE: WH); standard 1099.

Dividend policy? Growing — $1.65/sh FY2025 (+8% then +5%), ~2.1% yield, ~36% of adjusted EPS; well-covered.

How profitable is the business? Very, at the core — ~50% Adjusted EBITDA margin (Hotel Franchising ~55%), ~14–15% normalized ROIC.

Is net income diverging from cash from operations? (Fact:) Yes, in FY2025 — GAAP net income $193M (Revo-depressed) vs. OCF $367M; the divergence is the ~$160M non-cash Revo charge, not an accruals-quality problem. Normalized, the two reconcile.

Risks & Downside

What factors would cause the stock to decline? A RevPAR relapse (the low-income consumer rolling over); NUG deceleration as developer financing tightens; another franchisee-credit blow-up (a second Revo); a buyback pause to defend leverage; or a persistent de-rate as the market keeps reading the GAAP optics as deterioration.

Risk of a catastrophic loss? (Interpretation:) Low. Asset-light, ~$700M Adjusted EBITDA, FCF-generative, termed-out/mostly-fixed debt, ~$1.1B liquidity. The realistic bad case is a levered de-rating in a consumer recession (RevPAR + NUG compress together at 3.5x leverage), not insolvency.

Chance of a total loss? Negligible — a profitable, cash-generative franchisor with a durable contractual fee base.

Recent News & Events

Has the business environment changed recently? Yes — (1) RevPAR inflected positive in Q1-2026 after a soft 2025; (2) ancillary/credit-card economics stepped up (+21% Q1-2026); (3) the China MLA→direct pivot accelerated; (4) the Choice takeover overhang (and its ~$90 bid floor) is gone; offset by (5) the ~$160M Revo charge and a CFO transition.

Significant acquisitions? None material; the two foreclosed Revo hotels were consolidated (small).

Change in accounting policies? No substantive policy change; a Super 8 China reporting-methodology change (~$2M FY25 Adjusted EBITDA) and the FY2025 cost-reimbursement line collapsing to ~$0.

Recent changes — new markets, facilities, management? ECHO Suites expansion (20 open); China direct-franchising; AI/LLM direct-booking initiatives; CFO Amit Sripathi appointed (internal, late-2025); board expanded to 9 (Alexandra Jung added, Nov-2025); $650M senior notes issued (Feb-2026) terming out maturities.

APPENDIX B — Source Appendix

Wyndham Hotels & Resorts, Inc. (NYSE: WH) — Sources Report date: 2026-06-13. Primary public sources prioritized over secondary. All figures cross-checked against primary filings where available.

1. SEC Filings (primary — EDGAR, CIK 0001722684)

• Wyndham FY2025 Form 10-K (filed 2026-02-19; wh-20251231.htm). Business/brand/segment detail; unit & room counts; development pipeline; royalty rate; RevPAR; selected revenue data (royalties $541M / ancillary $317M / marketing-reservation-loyalty $562M); MD&A expense bridge (the $74M Revo loss provision + $86M Vienna House/Revo impairment + $47M→$2M Choice-defense transaction costs); Adjusted EBITDA reconciliation ($718M); debt note (TLB $1.5B/2030, TLA $337M/2027, $500M notes/Aug-2028, $1.0B revolver/2030, 2.8x first-lien, covenant-compliant, ~$840M liquidity); development-advance note ($343M, $32M amortization); issuer-purchases table (FY25 3.1M sh @ $85.73; 27.9M sh @ $69.37 cumulative since 2018). System: ~9,300 hotels / ~846,700 rooms / 95+ countries; 56% US rooms.
• Wyndham FY2023 Form 10-K — prior-period figures, Choice-defense disclosures, pre-Revo baseline.
• Wyndham Q1-2026 Form 10-Q (filed 2026-04-30) — net income $61M / EPS $0.80; revenue $327M (+3%); consolidated Adjusted EBITDA $156M (+8%); Super 8 China reporting change; hedge gains.
• 2026 DEF 14A (proxy) (filed 2026-03-25) — comp (annual incentive 75% Adjusted EBITDA / 25% global NUG; FY25 adj-EBITDA target $750M vs $718M actual; PSU = 3-yr adjusted EBIT-per-share); adjusted FCF $433M; beneficial ownership (Vanguard 11.05%, BlackRock 9.42%, T. Rowe 6.13%; Ballotti 832,015 / 1.11%; Holmes 373,782).
• 8-K corpus (43 filings, 2021–2026): Choice hostile-bid defense (2023–24); Q4/FY2025 earnings + Revo charge + dividend +5% to $0.43 (2026-02-18); CFO Michele Allen departure / Kurt Albert interim (2025-11-04); board expansion / Alexandra Jung director (2025-11-17); revolver amend/extend (Oct-2025); $650M 5.625% senior notes (Feb-2026); Amit Sripathi appointed CFO (2026-03-03).
• Choice takeover-defense materials: 37 Form 425, SC14D9C, 2 PREC14A, PRER14A, 18 DEFA14A (2023–2024) — Wyndham as the target.
• Form 3/4/5 insider corpus (443 Form 4, 3 Form 3, 7 Form 4/A, 28 Form 144; sampled): zero open-market purchases (code P); routine grants (A), tax-withholding (F), option exercise-and-sell (M/S), gifts (G — incl. CEO Ballotti).
• Schedule 13D/G corpus (33 filings): institutional ownership (Vanguard, BlackRock, T. Rowe).

EDGAR XBRL reconciled (edgar.sh concept WH us-gaap): NetIncomeLoss ($193M FY25 / $289M FY24), ShareBasedCompensation ($41M), revenue, OperatingIncomeLoss, LongTermDebt, PaymentsForRepurchaseOfCommonStock, WeightedAverageNumberOfDilutedSharesOutstanding.

2. Earnings Call Transcripts (primary management commentary — via ROIC.ai)

• Q1-2026 earnings call, 2026-04-30 (get_latest_earnings_call). FY2026 guidance (NUG +4–4.5%, RevPAR +1%/−1%, revenue $1.47–1.50B, Adjusted EBITDA $730–745M, adjusted EPS $4.62–4.80, net leverage 3.5x); RevPAR cadence (Jan −4% → Feb/Mar/Apr +1%); pipeline 259k rooms / 23rd consecutive quarter; ancillary +21%; China MLA→direct ~3x royalty; ECHO 20 open; Wyndham Rewards 124M / 54% direct; $650M 5.625% notes; $85M Q1 capital return; CFO Sripathi introduction.
• Q4 & FY2025 earnings call, 2026-02-19 (get_earnings_call_transcript). FeePAR premium (~30% domestic / 20% international); ~$1.43B fee revenue; $718M Adjusted EBITDA; adjusted EPS $4.58 (+6%); NUG +4%; 72k organic openings; 870 signings; ancillary +15%; >94% economy retention; Revo $160M charge; dividend +5% to $0.43. Full 2021–2026 call series available via list_earnings_calls.

3. Quantitative Data Sources

• ROIC.ai MCP (third-party aggregated; reconciled to EDGAR): get_income_statement, get_balance_sheet, get_cash_flow, get_profitability_ratios (ROIC 12.1% FY25 / 14.4% FY24), get_credit_ratios (net leverage 3.5x adj / 4.4x GAAP), get_enterprise_value (FY25 EV $8.30B; Q1-26 TTM EV $8.75B; net debt ~$2.5B), get_valuation_multiples (2018–2025: FY25 P/S 4.06x, EV/TTM-EBITDA 14.5x), get_company_profile.
• AZI valuation_index (own ~7-year post-spin history, COVID-spanning): composite 75.8th percentile; P/E 78.5th (Revo-trough-distorted), P/B 96.4th (buyback-thinned equity), P/S 52.5th (the clean read); price $79.39 (2026-06-12), TTM EPS $2.49.
• AZI news feed: count 0 (the familiar empty-feed pattern for a large clean filer; the timeline was built from 8-Ks + transcripts).
• AZI price CSV (download-data.php?t=WH): price/trend, 21/50/200-day EMAs, beta (~0.92), ~28% below the early-2024 ~$110 high.
• FactorsToday factor model (no-auth; statistical estimates): /stock-loadings/WH (Momentum −0.16, Growth −0.25 to −0.39, Quality +0.11, SmallSize +0.21–0.37, InterestRate −0.11, CreditRisk +0.16, Market ~1.0; R² ~0.42); /leaderboard/WH (1y −0.9%/Sharpe −0.10/maxDD −24.3%; 3y +5.2%; 5y +2.5%/Sharpe ~0.0; 3m +23.5%/Sortino 1.23); /stock-info/WH (beta 0.92, alpha −0.14, rs_6m +9.2%, rs_12m −2.3%); /related-stocks/WH (MAR 0.98, HLT 0.95, Hyatt 0.93, CHH 0.93, TNL, IHG).

6. Key figures (as used in the memo)

• System: ~9,300 hotels / ~846,700 rooms / 95+ countries; 56% US rooms; 25 brands; ~6,200 franchisees.
• FY2025: net revenue $1,429M (royalties $541M + ancillary $317M = ~$858M fee core; marketing/reservation/loyalty $562M pass-through). GAAP net income $193M / diluted EPS $2.50 (Revo-distorted); Adjusted EBITDA $718M (+4%); adjusted diluted EPS $4.58 (+6%). NUG +4%; pipeline >259,000 rooms / >2,200 hotels (23 consecutive quarters); 72,000 organic openings; 870 signings; royalty rate +7bp; Wyndham Rewards 124M / 54% direct.
• Revo (Vienna House) FY2025 charges: ~$160M ($86M impairment + $74M provision), non-cash/non-recurring.
• Balance sheet: total debt $2,563M; cash $64M; net debt ~$2,496M; ~3.5x net Adjusted EBITDA; ~$1.7B floating; ~$1.1B liquidity; first-lien 2.8x; negative tangible book (−$33/sh).
• Capital return FY2025: buybacks $266M (3.1M sh @ $85.73; $1.9B / 27.9M sh cumulative since 2018), dividend $127M ($1.65/sh, ~2.1% yield); diluted shares ~77M (down from ~98M at the 2018 spin).
• Ownership: no controlling family (Vanguard 11.05%, BlackRock 9.42%, T. Rowe 6.13%; CEO Ballotti 1.11%).
• Valuation: ~11.3x fwd EV/Adjusted EBITDA; ~16.9x fwd P/adjusted-EPS ($4.62–4.80 guide); ~8% FCF yield; P/S 52.5th percentile of own history.
• FY2026 guide: NUG 4–4.5%; RevPAR +1%/−1%; revenue $1.47–1.50B; Adjusted EBITDA $730–745M; adjusted EPS $4.62–4.80; net leverage 3.5x.

All figures cross-checked against primary filings where available; third-party aggregated data (ROIC, AZI, FactorsToday) reconciled to EDGAR and labeled. Management commentary treated as hypothesis and validated against filings.